AbCellera
| Company type | Public |
|---|---|
| Nasdaq: ABCL | |
| Industry | Contract Research Organization |
| Founded | 2012 |
| Headquarters | Vancouver, British Columbia |
| Revenue | 38 million (2023) |
| US $-163 million (2024) | |
Number of employees | 386 (2021) |
| Website | abcellera |
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization (CRO) that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.